Education
About Us
Working with TipRanks
Follow Us
Puma Biotechnology (PBYI)
NASDAQ:PBYI
Top Page
Puma Biotechnology
(NASDAQ:PBYI)
Select Model
Select Model
Rating:69Neutral
Price Target:
$7.00
▲(12.36% Upside)
Action:ReiteratedDate:03/03/26
The score is driven primarily by improving fundamentals (profitability since 2023, stronger balance sheet, and positive free cash flow), supported by a relatively low P/E. This is tempered by near-term earnings and cash-flow volatility highlighted on the earnings call (Q1 loss outlook, higher gross-to-net, rising R&D spend) and a mixed technical picture with limited momentum.
Positive Factors
Sustained profitability and high gross margins
Puma's multi-year return to GAAP profitability and persistently high gross margins imply durable cash generation from core product sales. High gross margins on NERLYNX support reinvestment in trials and operations and reduce reliance on external financing, strengthening long-term financial resilience.
Meaningfully stronger balance sheet (lower leverage)
A materially lower debt-to-equity ratio and restored positive equity provide lasting financial flexibility. Reduced leverage lowers refinancing and interest risks, enabling the company to fund ongoing clinical programs and commercialization without immediate capital raises, improving strategic optionality over months.
Clinical enrollment acceleration and upcoming interim data
Faster-than-expected enrollment and near-term interim readouts strengthen the company’s ability to expand indications and addressable market. Positive clinical timing can sustainably increase future prescribing, support label expansion, and de-risk long-term revenue growth beyond the current approved uses.
Negative Factors
Single-product revenue concentration
Heavy reliance on one marketed product creates structural revenue risk: reimbursement shifts, competitive entrants, or adverse safety/regulatory developments could significantly reduce cash flow. This concentration limits diversification and increases the company's sensitivity to single-product demand trends over months.
Elevated and rising gross-to-net deductions
Higher gross-to-net reduces realized product revenue per unit and introduces structural margin pressure tied to payer mix and government share. Sustained elevation lowers net sales predictability and can meaningfully compress long-term cash generation even if underlying volume grows.
Rising R&D/SG&A and modest cash buffer
Material planned increases in R&D and higher operating spend will raise cash outflows just as near-term revenue visibility is uneven. With cash modestly down YoY and periodic cash burn, sustained higher spending could strain liquidity or require financing, affecting strategic execution over the next several quarters.
Puma Biotechnology (PBYI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$316.96M
Dividend YieldN/A
Average Volume (3M)562.57K
Price to Earnings (P/E)9.6
Beta (1Y)0.83
Revenue Growth-12.96%
EPS Growth56.02%
CountryUS
Employees172
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.26
Shares Outstanding50,876,488
10 Day Avg. Volume391,965
30 Day Avg. Volume562,573
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)2.28
Price to Sales (P/S)1.30
P/FCF Ratio7.13
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue1.37
Enterprise Value/Gross Profit1.84
Enterprise Value/Ebitda5.30
Forecast
1Y Price Target
$5.00Price Target Upside-19.74% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)0.4
Revenue Forecast (FY)$220.00M
Puma Biotechnology Business Overview & Revenue Model
Company DescriptionPuma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
How the Company Makes MoneyPuma Biotechnology generates revenue primarily through the sales of its flagship product, NERLYNX. The company earns money by selling this prescription drug to wholesalers, specialty pharmacies, and distributors, who then supply it to healthcare providers and patients. Additionally, Puma may receive milestone payments and royalties from licensing agreements or partnerships with other pharmaceutical companies interested in marketing NERLYNX in regions outside the United States. These collaborations can significantly contribute to the company's earnings by expanding its market reach and leveraging the distribution and marketing capabilities of its partners.
Puma Biotechnology Earnings Call Summary
Earnings Call Date:Feb 26, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Apr 30, 2026
Earnings Call Sentiment Positive
The call presented meaningful commercial momentum (QoQ and YoY revenue and volume growth), a large one-time royalty uplift, continued GAAP profitability in Q4 and faster-than-expected enrollment in a key Phase II breast cancer trial with interim data expected in Q2 2026. Offsetting this are soft new prescription trends, elevated gross-to-net deductions and higher near-term operating and R&D spend (with an anticipated Q1 2026 loss), plus inventory-related seasonality and modest cash depletion. On balance the company shows strong operational and clinical progress with manageable financial headwinds and near-term volatility.Q4-2025 Updates
Positive Updates
Revenue Growth — Q4 2025
Total revenue of $75.5M in Q4 2025; net product revenue (NERLYNX) of $59.9M, up from $51.9M in Q3 2025 (+15.4% QoQ) and up from $54.4M in Q4 2024 (+10.2% YoY). Gross NERLYNX revenue was $82.9M in Q4 versus $70.0M in Q3.
Royalty Revenue Spike
Royalty revenue of $15.6M in Q4 2025 versus $2.6M in Q3 2025 and $4.7M in Q4 2024 — driven by shipments to partner in China (large QoQ increase).
Volume and Demand Momentum
Ex-factory bottle sales of 3,298 in Q4 2025, up ~12% QoQ and ~11% YoY. Demand increased ~7% QoQ and ~7% YoY; specialty distributor (SD) channel grew ~17% QoQ and ~46% YoY.
Profitability Maintained
GAAP net income of $13.4M in Q4 2025 (vs. $8.8M in Q3 2025). Non-GAAP net income was $15.1M for Q4. Company reported full-year 2025 positive net income (third consecutive profitable year).
Clinical Development Progress — ALISCA-Breast1
ALISCA-Breast1 enrolled faster than expected: trial originally planned for 150 patients and anticipated to finish enrollment Dec 2026, but reached 150 in Feb 2026 and currently has 164 enrolled; interim data expected in Q2 2026 (safety/efficacy analysis after ~75 randomized with 2 tumor assessments).
Clinical Progress — ALISCA-Lung1
ALISCA-Lung1 has 79 patients enrolled, with protocol amended to increase dose from 50 mg BID to 60 mg BID to address lower PK; 27 patients enrolled at 60 mg with acceptable safety so far and company planning to seek FDA amendment to increase to 70 mg; interim data expected in Q2 2026 (~60 patients).
Forward Financial Guidance
FY2026 net NERLYNX product revenue guidance $194M–$198M; FY2026 gross-to-net expected 27.5%–28.5%; royalties guidance $20M–$23M for the referenced fiscal period; Q1 2026 product revenue guidance $36M–$39M.
Negative Updates
Decline in New Prescriptions and Enrollments
New prescriptions (NRx) down ~11% QoQ and ~6% YoY in Q4 2025. Enrollments declined ~5% QoQ and ~3% YoY; TRx declined ~6% YoY (though TRx was slightly up QoQ ~2%).
Inventory Build Impacting Revenue Mix
Product revenue in Q4 was impacted by an estimated $5.7M inventory build at specialty pharmacies/distributors (inventory increased by ~343 bottles in Q4, following increases in prior quarters), which typically results in a Q1 channel burn-off and lower Q1 revenue.
Rising Gross-to-Net and Government Deductions
Gross-to-net adjustments increased to ~27.8% in Q4 2025 from 25.9% in Q3 2025 and are expected to remain elevated in 2026 (guidance 27.5%–28.5% for full-year and ~29.5%–30.5% for Q1), driven by higher Medicare/Medicaid share and government chargebacks.
Higher Cost of Sales and Ongoing Amortization
Cost of sales increased to $23.2M in Q4 (vs $12.2M in Q3), including ~$2.4M quarterly amortization of intangible assets related to the neratinib license — a continuing expense pressure going forward.
Near-Term Profitability Pressure — Q1 2026 Loss Expectation
Company expects a Q1 2026 net loss of $8M–$10M and notes Q1 is typically the weakest quarter due to inventory burn-off, implying near-term earnings volatility despite full-year guidance.
Rising R&D Spend and Increased Operating Expenses
R&D expenses were $16.8M in Q4 and company expects R&D to increase 30%–35% year-over-year in 2026 (driven by clinical trial progress); SG&A expected to increase 3%–5% — both factors will increase cash outlays.
Cash and Receivables Considerations
Cash, cash equivalents and marketable securities were $97.5M at 12/31/2025 (down from ~$101M a year earlier). Q4 cash burn was ~$3.1M (vs ~$1.6M in Q3), accounts receivable of $53.7M and DSO ~48 days; outstanding principal debt ~ $22M after an $11.1M loan payment, indicating liquidity/cash flow monitoring needed.
Company Guidance
Puma guided to full‑year 2026 net NERLYNX product revenue of $194–$198 million with a full‑year gross‑to‑net adjustment of 27.5%–28.5% and anticipated royalties from partners of about $20–$23 million (the company also said it does not expect license revenue in 2025), and cited expected full‑year net income of roughly $10–$13 million; for Q1 2026 management forecast net product revenue of $36–$39 million, royalty revenue of $2–$3 million, a Q1 gross‑to‑net of ~29.5%–30.5% and a Q1 net loss of $8–$10 million. It further said it will continue to amortize milestone/license costs of about $2.4 million per quarter to cost of sales, expects SG&A to rise 3%–5% and R&D to rise 30%–35% year‑over‑year (driven by clinical progress), and warned gross‑to‑net pressure in 2026 from sustained government chargebacks and Medicare/Medicaid share.Puma Biotechnology Financial Statement Overview
Summary
Multi-year turnaround with sustained profitability since 2023, strong gross margins, improved leverage (debt-to-equity down materially by 2025), and positive free cash flow in 2023–2025. Offsets include largely flat revenue trajectory, some year-to-year operating profitability inconsistency, and a slight free-cash-flow dip in 2025.Income Statement
Revenue has been relatively stable over the past several years (down in 2022, then modest growth in 2023 and a slight decline in 2024, followed by a return to growth in 2025). Profitability has materially improved versus 2020–2021 losses, with solid gross margins (~72%–76%) and healthy net margins in 2023–2025 (roughly 9%–14%). A watch item is that operating profitability appears less consistent year-to-year (including a 2025 operating margin datapoint shown as 0%), even though net income remains strong.72
Positive
Balance Sheet
The balance sheet has strengthened meaningfully as leverage has come down: debt-to-equity improved from very high levels in 2022–2023 to a much more conservative level in 2025 (~0.22), driven by both lower debt and higher equity. Equity is now firmly positive versus negative in 2020–2021, and returns on equity are strong in 2023–2025. The main residual risk is that this is a company coming out of a historically leveraged period, so maintaining equity strength and disciplined borrowing remains important.76
Positive
Cash Flow
Cash generation has improved sharply from 2022, with positive operating cash flow and free cash flow in 2023–2025 and strong conversion of earnings into free cash flow (near 1.0 in 2024–2025). However, operating cash flow as a share of revenue remains moderate (roughly low-to-mid teens recently), and free cash flow growth turned slightly negative in 2025 after being positive in 2023–2024, suggesting some recent pressure on incremental cash generation.69
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 228.37M | 230.47M | 235.64M | 228.03M | 253.16M |
| Gross Profit | 170.21M | 166.06M | 172.96M | 172.94M | 189.45M |
| EBITDA | 53.34M | 48.08M | 47.52M | 21.89M | -4.69M |
| Net Income | 31.11M | 30.28M | 21.59M | 2.00K | -29.13M |
Balance Sheet | |||||
| Total Assets | 216.30M | 213.33M | 230.53M | 222.06M | 226.59M |
| Cash, Cash Equivalents and Short-Term Investments | 97.53M | 100.97M | 95.94M | 81.07M | 82.11M |
| Total Debt | 28.55M | 74.08M | 111.49M | 114.28M | 116.64M |
| Total Liabilities | 85.96M | 121.21M | 177.09M | 200.45M | 229.03M |
| Stockholders Equity | 130.34M | 92.13M | 53.44M | 21.61M | -2.45M |
Cash Flow | |||||
| Free Cash Flow | 41.73M | 38.86M | 14.37M | -22.83M | 20.65M |
| Operating Cash Flow | 41.80M | 38.92M | 27.01M | -15.83M | 20.65M |
| Investing Cash Flow | -36.19M | -20.44M | -19.13M | 7.10M | -10.88M |
| Financing Cash Flow | -45.20M | -33.85M | 0.00 | 12.22M | -31.93M |
Puma Biotechnology Technical Analysis
Negative
6.23
Price Trends
6.49
Negative
5.86
Positive
4.95
Positive
Market Momentum
<0.01
Positive
46.48
Neutral
38.69
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PBYI, the sentiment is Negative. The current price of 6.23 is below the 20-day moving average (MA) of 6.81, below the 50-day MA of 6.49, and above the 200-day MA of 4.95, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 46.48 is Neutral, neither overbought nor oversold. The STOCH value of 38.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PBYI.
Puma Biotechnology Risk Analysis
Puma Biotechnology disclosed 58 risk factors in its most recent earnings report. Puma Biotechnology reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Puma Biotechnology Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $316.96M | 9.56 | 39.69% | ― | -12.96% | 56.02% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $604.53M | -0.10 | ― | ― | ― | -1072.48% | |
49 Neutral | $330.40M | -4.86 | ― | ― | -3.91% | 37.89% | |
48 Neutral | $192.31M | -10.73 | ― | ― | 12.60% | 58.23% | |
46 Neutral | $218.51M | -2.46 | -46.09% | ― | -80.88% | -388.61% | |
43 Neutral | $177.38M | -3.26 | -96.44% | ― | ― | 46.68% |
* Healthcare Sector Average
PBYI
Puma Biotechnology
6.23
2.61
72.10%
HRTX
Heron Therapeutics
1.02
-1.34
-56.78%
VYGR
Voyager Therapeutics
3.93
-0.21
-5.07%
FHTX
Foghorn Therapeutics
5.64
1.14
25.33%
VOR
Vor Biopharma
14.56
-5.14
-26.09%
TNYA
Tenaya Therapeutics
0.82
0.35
74.26%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.